| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
While CP-465022 1 µM for 10 minutes reduced the current measured for 8 seconds during NMDA application by 26%, it had little effect on NMDA-induced peak currents. In primary cultures of cortical and cerebellar granule neurons, CP-465,022 at 10 µM inhibits NMDA-induced peak currents in cortical neurons by 36%, as measured at 8 seconds times 70% d [1]. In cultured rat cerebellar granule neurons, CP-465022 1 µM inhibited peak NMDA currents for 10 minutes at an average inhibition rate of 19%. At 8 seconds, the NMDA current inhibition rate was measured and found to be 45%, in agreement with cortical neurons. A comparable circumstance was noted [1]. In the voltage-clamped rat hippocampal region, CP-465022 (100 nM – 10 µM) suppresses kainate-induced whole-cell currents. At 100 nM, CP465,022 suppresses kainate currents that develop in 200 seconds, and at 500 nM and 1 µM, CP-465,022 nearly completely suppresses this time range (99.3%)[1].
|
|---|---|
| References |
[1]. J T Lazzaro, et al. Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist. Neuropharmacology. 2002 Feb;42(2):143-53.
|
| Molecular Formula |
C26H24CLFN4O
|
|---|---|
| Molecular Weight |
462.9464
|
| CAS # |
199655-36-2
|
| Related CAS # |
CP-465022 maleate;199656-46-7;CP-465022 hydrochloride;1785666-59-2
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
ClC1=C([H])C([H])=C([H])C([H])=C1N1C(C2C([H])=C(C([H])=C([H])C=2N=C1/C(/[H])=C(\[H])/C1=C([H])C([H])=C([H])C(C([H])([H])N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])[H])=N1)F)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~108.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1601 mL | 10.8003 mL | 21.6006 mL | |
| 5 mM | 0.4320 mL | 2.1601 mL | 4.3201 mL | |
| 10 mM | 0.2160 mL | 1.0800 mL | 2.1601 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
